InMed Pharmaceuticals (INM)
(Delayed Data from NSDQ)
$0.27 USD
-0.01 (-1.87%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $0.28 +0.01 (2.53%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.27 USD
-0.01 (-1.87%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $0.28 +0.01 (2.53%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update
by Zacks Equity Research
Updates from CTMX and APLS are the key highlights from the biotech sector during the past week.
InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program
by Zacks Equity Research
InMed Pharmaceuticals (INM) surges on receiving research grant funding from the Natural Sciences and Engineering Research Council of Canada (NSERC) to investigate its cannabinoid drug candidates.
InMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -8.70% and 27.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
InMed Pharmaceuticals Inc. (INM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -29.17% and 6%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
InMed Pharmaceuticals Inc. (INM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of 28.57% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?